Wuliangye's 1H26 preliminary earnings recovery below expectations; Goldman Sachs maintains Sell rating

Overview

This report is Goldman Sachs' review of Wuliangye Yibin's 000858.SZ preliminary earnings results. The company expects substantial year-on-year growth in 1H26 net profit, mainly due to the low base following the restatement of 1H25 results; however, earnings recovery remains notably inadequate compared with 1H24 levels. Goldman Sachs believes that although Common Wuliangye sell-through has achieved double-digit growth year-to-date, the company's shipment side remains in a de-stocking process, with recovery slower than expected.

Core views

The core view is that the quality of Wuliangye's 1H26 and 2Q26 earnings rebound is weak. The midpoint of 1H26 net profit is Rmb8,965mn, recovering to only approximately 47% of 1H24 net profit of Rmb19.1bn; the midpoint of 2Q26 net profit is Rmb902mn, up 335% year-on-year but still only a small fraction of 2Q24 net profit of Rmb5.0bn. Goldman Sachs maintains its Sell rating, reflecting a cautious view on de-stocking, shipment recovery, and the pace of recovery in premium baijiu demand.

Analysis framework

The report starts with the company's preliminary net profit range, breaks down 1H26 and implied 2Q26 net profit performance, and compares these figures with the low-base year of 1H25, the normal high-base periods of 1H24/2Q24, and Goldman Sachs' own forecasts to assess the true strength of earnings recovery. The valuation applies a 2027E P/E multiple discounted to mid-2027.

Methodology notes

• Valuation methodsP/E Target Price Method

  A 12-month target price of Rmb70 is derived using 16x 2027E P/E discounted to mid-2027 at a 7.8% cost of equity.

  This method combines forward annual earnings forecasts with a target P/E multiple, then discounts the result using the cost of equity to derive the current 12-month target price.

• Factor AnalysisGS Factor Profile

  Goldman Sachs compares the company with the market and industry peers across four attributes: Growth, Financial Returns, Multiple, and Integrated.

  Growth is based on forward revenue, EBITDA, and EPS growth; Financial Returns is based on ROE, ROCE, and CROCI; Multiple is based on valuation metrics such as P/E, P/B, and EV/EBITDA; Integrated combines growth, returns, and valuation percentiles.

• M&A AssessmentM&A Rank

  Goldman Sachs uses levels 1 to 3 to assess the probability that a covered company becomes an acquisition target.

  1 represents a high probability of 30% to 50%, 2 represents a medium probability of 15% to 30%, and 3 represents a low probability of 0% to 15%; Rank 1 or 2 may be incorporated into the target price components.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Wuliangye Yibin 000858.SZ

  Covered company; Goldman Sachs assigns a Sell rating.

  Strengths

  The company retains a strong premium baijiu brand foundation, while Common Wuliangye sell-through has achieved double-digit growth year-to-date.

  Weaknesses

  1H26 and 2Q26 net profit remain substantially below 2024 levels, with de-stocking on the shipment side causing slower-than-expected recovery.

  Comparison

  The report compares 1H26 with the low base of 1H25, the normal high base of 1H24, and Goldman Sachs' forecasts, showing that earnings recovery is weaker than the headline year-on-year growth rate suggests.

  Risks

  Successful new product launches, easing competition in the ultra-premium segment, policy stimulus driving a recovery in premium baijiu demand, or improved shareholder returns could create upside risks.

• Kweichow Moutai / Luzhou Laojiao

  Peer competition reference in the premium and ultra-premium baijiu segments.

  Strengths

  As key companies in the ultra-premium baijiu competitive landscape, changes in their competitive positioning could affect Wuliangye's pricing and demand recovery.

  Weaknesses

  The report does not provide specific financial data for these peers.

  Comparison

  Goldman Sachs notes that reduced ultra-premium competition from Moutai/Laojiao would constitute an upside risk for Wuliangye.

  Risks

  If competition does not ease, Wuliangye's premium baijiu recovery may remain under pressure.

Key data

• 1H26 Preliminary Net ProfitRmb8,730mn to Rmb9,200mnUp 89% to 99% year-on-year, compared with the low base of restated 1H25 net profit of Rmb4.6bn.
• 1H26 Net Profit MidpointRmb8,965mnUp 94% year-on-year and 15% below Goldman Sachs' forecast of Rmb10,559mn.
• Recovery Versus 1H2446% to 48%1H24 net profit was Rmb19.1bn.
• Implied 2Q26 Net ProfitRmb667mn to Rmb1,137mnUp 222% to 448% year-on-year, with a midpoint of Rmb902mn.
• Recovery Versus 2Q2413% to 23%2Q24 net profit was Rmb5.0bn.
• RatingSellGoldman Sachs maintains its Sell rating.
• 12-Month Target PriceRmb70Based on 16x 2027E P/E and discounted at a 7.8% cost of equity.

Impact & implications

For investment implications, the report emphasizes that Wuliangye's strong year-on-year earnings growth should not be simply interpreted as a strong fundamental recovery, because the comparison base is low and performance remains notably weak relative to 2024 levels. If de-stocking persists, shipment and profit recovery may continue to lag the improvement in sell-through, constraining valuation recovery and share price performance.

Risks

• Successful launches of new products, particularly in the mid-end price segment, could improve growth expectations.
• Reduced competition from Moutai/Laojiao in the ultra-premium baijiu segment could improve Wuliangye's competitive environment.
• Significant policy stimulus driving a recovery in premium baijiu demand could create upside for earnings and valuation.
• Further enhancement of shareholder returns could support the share price.
• A longer-than-expected de-stocking period could continue to suppress shipment and earnings recovery.

What to watch

• Whether the shipment side shifts from de-stocking to normal inventory replenishment.
• Whether double-digit growth in Common Wuliangye sell-through can translate into revenue and profit recovery.
• The slope of 2H26 net profit recovery and its gap relative to 2024 levels.
• Whether premium baijiu demand is supported by policy stimulus or the recovery of consumption scenarios.
• The intensity of competition from peers such as Moutai and Laojiao in the ultra-premium price segment.
• Whether the company launches effective new products and improves performance in the mid-end price segment.